Guardant Health, INC 10-K annual reports

Guardant Health, a precision oncology company, reported a 33% increase in total revenue to $982.0 million for fiscal year 2025, driven by growth across its oncology, biopharma, and newly commercialized screening segments, despite continued net losses.

Guardant Health reports revenue growth in its 2024 10-K filing, driven by increased testing volume and reimbursement, but continues to operate at a net loss.

Guardant Health's 2023 10-K filing highlights its commitment to precision oncology, expansion of product offerings, and strategic collaborations amidst ongoing financial losses and a complex regulatory landscape.